Subfoveal choroidal thickness changes after intravitreal bevacizumab therapy for central serous chorioretinopathy

Ünlü, Cihan; Erdoğan, Gürkan; Gezginaslan, Tuğba Aydoğan; Akçay, Betül İlkay Sezgin; Kardeş, Esra; Bozkurt, Tahir Kansu

doi:10.5935/0004-2749.20160088

Cited by 8 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although Ünlü, et al in their study on intravitreal Bevacizumab concluded that there was no statistical difference anatomically between the injected and the observation groups, they found that the vision in the observation group was markedly better than the injected group this difference from our study may be owed to two factors; the first factor is that Ünlü, et al study was retrospective and did not differentiate between acute and chronic CSCR unlike our study which was on acute cases only, and the other factor is the longer mean duration of follow up in Ünlü ,et al's study which was 12.1 ± 12.8 (range: 3 to 43) months in the injected group and 8.8 ± 9.4 (range: 3 to 40) months in the observation group while in our study all patients were followed up to 4 months (24) .…”

Section: Discussioncontrasting

confidence: 64%

Effectivness of Intravitreal Ranibizumab (Lucentis) in Acute Central Serous Chorioretinopathy Treatment

Abdulhadi,

Bukhatwa

2024

Ain Shams Medical Journal

View full text Add to dashboard Cite

Background/Aims: To study the effectiveness of intravitreal ranibizumab injection (IVR) in the treatment of acute central serous chorioretinopathy (CSCR).Methods: A Prospective, randomized, single-center, parallel-arm, controlled trial study the involved patients had symptoms of CSCR with less than 3 months duration. Patients (n = 50/ divided into 2 groups) the anti-VEGF group with 30 patients injected with intravitreal Ranibizumab(IVR) (0.5 mg/0.05 ml) and an observation group where 20 patients were observed, each group were followed for 4 months. Best-corrected visual acuity (BCVA), and central macular thickness (CMT) were assessed by Ocular coherent tomography (OCT) for first baseline and then at regular follow-ups.Results: All patients had improved and increased BCVA, with decreased CMT, and resolution of the subretinal fluid. The mean CMT in IVR and observation groups was 117. 33±46.2µm and 196.70±36.9µm, respectively (P = 0.670) The mean BCVA and mean CMT improved significantly in both groups at 4 weeks , but the changes were not significantly different between both groups at 4months. Conclusions: both IVR and observation for acute CSCR improved the resolution of subretinal fluid. BCVA and CMT did not differ at 4 months, between IVR and observation groups. So we advised a Further studies are required to determine the long-term benefits of IVR.

show abstract

Section: Discussioncontrasting

confidence: 64%

Effectivness of Intravitreal Ranibizumab (Lucentis) in Acute Central Serous Chorioretinopathy Treatment

Abdulhadi,

Bukhatwa

2024

Ain Shams Medical Journal

View full text Add to dashboard Cite

show abstract

“…In acute CSCR, intravitreal bevacizumab injection was not superior to observation. [ 19 ] In our study, acute CSCR cases were observed without any treatment. Although not statistically significant, a decrease in SFCT was observed, similar to the literature by Unlu et al Besides, in our study, changes in CT at neighboring points were analyzed and a significant reduction was found at N1500.…”

Section: Discussionmentioning

confidence: 79%

Choroidal thickness changes in non-treated acute and ranibizumab-treated chronic central serous chorioretinopathy

2018

View full text Add to dashboard Cite

To evaluate the changes in subfoveal retinal, and choroidal thicknesses (CT) in the non-treated acute and the ranibizumab-treated chronic central serous chorioretinopathy (CSCR) patients.This retrospective study included 32 eyes of 32 consecutive patients with CSCR. There were 12 patients who presented with a spontaneous resolution of CSCR (Group 1) and 20 patients who were treated with ranibizumab for persistent subretinal fluid (SRF) (Group 2). Optical coherence tomography (OCT) imaging of subfoveal retinal thickness and enhanced depth imaging OCT of CT at subfoveal; at nasal and temporal 500 μm (T500); at nasal and temporal 1500 μm (T1500) were analyzed. The Student t test and multivariate analysis were used to compare variables within and between groups, respectively and correlations were analyzed using Pearson correlation coefficient. A P value of P < .05 was accepted as significant.The mean patient age was 38.94 ± 8.41 years (range, 20–53 years). Female/male ratio was 4/28. The mean duration of follow-up was 21.6 ± 8.2 months in the chronic CSCR group. Visual acuity improved and central foveal thickness (FT) decreased significantly in both groups. CT decreased significantly only at nasal 1500 μm (N1500) in the acute group and at all measured points in the chronic group compared with baseline, except at T500 (P = .07). No significant difference in central FT was detected between the 2 groups. Compared with the acute group, baseline subfoveal CT was significantly higher in chronic patients. There was a significant difference between the groups in baseline and final CT at T500. No significant difference was found at T1500. At nasal 500 μm and N1500, the difference between the groups was significant only for final CT values.Chronic CSCR was associated with higher baseline CT values in the subfoveal region and at T500. CT significantly decreased at most of the measured points in ranibizumab-treated chronic CSCR patients, whereas it significantly decreased only at 1 point in spontaneously resolved acute CSCR patients.

show abstract

“…The efficacy of PDT for chronic CSC has been reported previously, however [ 2 , 3 , 11 ], and it is ethically challenging to follow up on chronic CSC without treatment. In addition, since the current results are relatively large compared to choroidal changes during spontaneous remission in acute CSC [ 35 , 36 ], we believe that the choroidal changes observed in this study were related to PDT.…”

Section: Discussionmentioning

confidence: 86%

Effect of photodynamic therapy on choroid of the medial area from optic disc in patients with central serous chorioretinopathy

et al. 2023

View full text Add to dashboard Cite

Purpose To explore the effect of photodynamic therapy (PDT) on the choroid of medial area from optic disc and factors correlated with treatment outcomes, we evaluated choroidal changes using ultra-widefield optical coherence tomography (UWF-OCT) after PDT for central serous chorioretinopathy (CSC). Methods In this retrospective case-series, we included CSC patients who received a standard-dose of full-fluence PDT. UWF-OCT were examined at baseline and 3 months after treatment. We measured choroidal thickness (CT), classified into central, middle, and peripheral sectors. We examined CT changes after PDT by sectors and treatment outcome. Results Twenty-two eyes of 21 patients (20 males; mean age 58.7 ± 12.3 years) were included. CT reduction after PDT was significant in all sectors, including peripheral areas: supratemporal, 330.5 ± 90.6 μm vs. 237.0 ± 53.2 μm; infratemporal, 240.0 ± 89.4 μm vs. 209.9 ± 55.1 μm; supranasal, 237.7 ± 59.8 vs 209.3 ± 69.3 μm; infranasal, 172.6 ± 47.2 μm vs. 155.1 ± 38.2 μm (P < 0.001, for all). In patients with retinal fluid resolution, despite no apparent difference in baseline CT, there was more significant reduction after PDT in supratemporal and supranasal peripheral sectors, compared with patients without resolution: supratemporal, 41.9 ± 30.3 μm vs. −1.6 ± 22.7 μm; supranasal, 24.7 ± 15.3 μm vs. 8.5 ± 3.6 μm (P < 0.019, for both). Conclusions Whole CT decreased after PDT, including in medial areas from optic disc. This may be associated with the treatment response of PDT for CSC.

show abstract

Subfoveal choroidal thickness changes after intravitreal bevacizumab therapy for central serous chorioretinopathy

Cited by 8 publications

References 29 publications

Effectivness of Intravitreal Ranibizumab (Lucentis) in Acute Central Serous Chorioretinopathy Treatment

Effectivness of Intravitreal Ranibizumab (Lucentis) in Acute Central Serous Chorioretinopathy Treatment

Choroidal thickness changes in non-treated acute and ranibizumab-treated chronic central serous chorioretinopathy

Effect of photodynamic therapy on choroid of the medial area from optic disc in patients with central serous chorioretinopathy

Contact Info

Product

Resources

About